findmyKOL
Clinical trialNCT03611738Active, not recruitingPhase 1Interventional

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment21EGFR Negative Non-Small Cell Lung CancerLung CancerNon-small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IIIBStage IV Non-small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia®) used in combination with docetaxel (Taxotere®) will have on participants and their cancer. The results will help to determine the best safe dose of the combination of the medications Ceritinib (Zykadia®) and docetaxel (Taxotere®) and to find out if this combination of drugs will help people that have this type of Non-small Cell Lung Cancer (NSCLC).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Andreas Saltos, M.D.

    H. Lee Moffitt Cancer Center and Research Institute

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Advent Health Orlando

    Orlando, Florida, United States

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ceritinib →Docetaxel →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Feb 2019
Primary completion
28 Apr 2025
Completion
31 Mar 2027
Last update posted
15 May 2026
Registered enrollment
21
Registry id
NCT03611738
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.